SCHEMBL7010700

SCHEMBL7010700

COc1ccc2nc([S+]([O-])Cc3ncc(C)c(OC)c3C)n(S(=O)(=O)c3ccc(OCC(=O)NCC(N)=O)cc3)c2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.38
HPGDS O60760 1/20 0.37
ALDH1A1 P00352 6/20 0.35
KMT2A Q03164 4/20 0.35
WDR5 P61964 2/20 0.35
BRS3 P32247 2/20 0.35
MAPT P10636 2/20 0.35
KDM4E B2RXH2 1/20 0.35
DDAH1 O94760 1/20 0.35
ABCB11 O95342 1/20 0.35
ATP1A1 P05023 1/20 0.35
ATP1B1 P05026 1/20 0.35
CYP1A2 P05177 1/20 0.35
CHRM2 P08172 1/20 0.35
ABCB1 P08183 1/20 0.35
CYP3A4 P08684 1/20 0.35
ADORA3 P0DMS8 1/20 0.35
CHRM1 P11229 1/20 0.35
ATP1A3 P13637 1/20 0.35
ATP1B2 P14415 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7007139 0.94 HPGDS (0.38) CYP2C9HPGDSALDH1A1KMT2AWDR5
SCHEMBL7008064 0.92 CYP2C9 (0.42) CYP2C9ALDH1A1KMT2AWDR5BRS3
SCHEMBL5763595 0.90 CYP2C9 (0.42) CYP2C9ALDH1A1KMT2AWDR5BRS3
SCHEMBL5332714 0.90 CYP2C9 (0.42) CYP2C9ALDH1A1KMT2AWDR5BRS3
SCHEMBL5332710 0.90 CYP2C9 (0.42) CYP2C9ALDH1A1KMT2AWDR5BRS3
SCHEMBL14495759 0.89 CYP2C9 (0.42) CYP2C9ALDH1A1KMT2AWDR5BRS3
SCHEMBL5370630 0.89 CYP2C9 (0.42) CYP2C9ALDH1A1KMT2AWDR5BRS3
SCHEMBL5367365 0.89 CYP2C9 (0.42) CYP2C9ALDH1A1KMT2AWDR5BRS3
SCHEMBL5763585 0.88 CYP2C9 (0.42) CYP2C9ALDH1A1KMT2AWDR5BRS3
SCHEMBL7009249 0.87 CYP2C9 (0.41) CYP2C9ALDH1A1KMT2AWDR5BRS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6559167-B1 Prodrugs of the pyridyl methyl sulfinyl benzimidazole type proton pump inhibitor drugs have a hydrolyzable arylsulfonyl or heteroarylsulfonyl group attached to the benzimidazole nitrogen. The prodrugs of the invention hydrolyze under REGENTS OF THE UNIVERSITY OF CALIFORNIA 2003-05-06 US claimed
EP-1105387-B1 PRODRUGS OF PROTON PUMP INHIBITORS WINSTON PHARMATEUTICALS LLC (US) 2003-01-29 EP claimed
EP-1105387-A1 PRODRUGS OF PROTON PUMP INHIBITORS Partnership of Michael E. Garst, George Sachs and Jai Moo Shin (US) 2001-06-13 EP claimed
WO-2000009498-A1 PRODRUGS OF PROTON PUMP INHIBITORS PARTNERSHIP OF MICHAEL E. GARST, GEORGE SACHS AND JAI MOO SHIN (US) 2000-02-24 WO claimed
US-6559167-B1 Prodrugs of the pyridyl methyl sulfinyl benzimidazole type proton pump inhibitor drugs have a hydrolyzable arylsulfonyl or heteroarylsulfonyl group attached to the benzimidazole nitrogen. The prodrugs of the invention hydrolyze under REGENTS OF THE UNIVERSITY OF CALIFORNIA 2003-05-06 US disclosed
EP-1105387-B1 PRODRUGS OF PROTON PUMP INHIBITORS WINSTON PHARMATEUTICALS LLC (US) 2003-01-29 EP disclosed
EP-1105387-A1 PRODRUGS OF PROTON PUMP INHIBITORS Partnership of Michael E. Garst, George Sachs and Jai Moo Shin (US) 2001-06-13 EP disclosed
WO-2000009498-A1 PRODRUGS OF PROTON PUMP INHIBITORS PARTNERSHIP OF MICHAEL E. GARST, GEORGE SACHS AND JAI MOO SHIN (US) 2000-02-24 WO disclosed